Drug Intake and Actinic Keratosis: 
A Case-Control Study

Andrea Sechi¹, Ambra di Altobrando¹, Eugenio Cerciello¹, Elisa Maietti², Annalisa Patrizi¹, Francesco Savoia¹

¹ Dermatology, IRCCS Policlinico di Sant’Orsola. Department of Experimental, Diagnostic and Specialty Medicine, Alma Mater Studiorum University of Bologna, Italy
² Department of Biomedical and Neuromotor Sciences, University of Bologna, Italy

Key words: drug reaction, photosensitivity, actinic keratosis, angiotensin receptor blockers, antiplatelet drug

Citation: Sechi A, di Altobrando A, Cerciello E, Maietti E, Patrizi A, Savoia F. Drug intake and actinic keratosis: a case-control study. Dermatol Pract Concept. 2021;11(2):e2021031. DOI: https://doi.org/10.5826/dpc.1102a31

Accepted: February 3, 2021; Published: April 12, 2021

Copyright: ©2021 Sechi et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License BY-NC-4.0, which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original authors and source are credited.

Funding: None.

Competing interests: The authors have no conflicts of interest to disclose.

Authorship: A.S and A.D. contributed equally to this work. All authors have contributed significantly to this publication.

Corresponding author: Andrea Sechi, MD, Dermatology -IRCCS Policlinico di Sant’Orsola. Department of Experimental, Diagnostic and Specialty Medicine, Alma Mater Studiorum University of Bologna, Italy, Via Massarenti 9, 40138 Bologna, Italy. Email: andrea.sechi@hotmail.com

ABSTRACT

Background: Actinic keratosis (AK) is a form of premalignant keratinocyte dysplasia. Recently, the role of photosensitizing drugs in the development of AK has been postulated.

Objective: This study evaluated a possible association between the use of photosensitizing drugs and the development of AK. A secondary aim was to identify a possible association between any medication other than those primarily examined and AK.

Methods: A single-center, case-control study assessed the cumulative drug exposure of 90 patients with AK and 90 controls visiting a dermatology service for other skin ailments. Before the visit, patients were interviewed to collect data on daily therapy and the lag-time of discontinued drugs within the last 2 years, and to record the drug’s active ingredient, dosage, and duration of therapy. In addition, sociodemographic characteristics including age, sex, educational level, skin phototype, and cumulative sun exposure habits were gathered.

Results: By logistic regression, exposures to angiotensin II receptor blockers (ARBs) and antiplatelet agents were identified as independent risk factors for the development of AK. ARB intake was associated with AK only at high exposure (OR = 13.6; 95% CI, 2.0-93.8). The use of antiplatelet drugs was borderline, yet not significant, at low exposure (OR = 3.31; 95% CI, 0.86-12.7), but increased in a dose-dependent manner. The strongest correlation was found at the highest cumulative dose (>1100 dose-unit-years (OR = 4.38; 95% CI, 1.16-16.6).

Conclusions: High exposure to ARBs and antiplatelet agents may promote AK carcinogenesis in at-risk patients.
Introduction

Actinic keratosis (AK) is a common skin lesion caused by the proliferation of atypical keratinocytes. In the literature, AK is considered as a form of either premalignant dysplasia or in situ squamous cell carcinoma (SCC). The finding that 60% of SCCs arise at the site of a previous AK supports the pathogenetic model of a continuous progression between AK and SCC [1]. AKs may evolve following 1 of 3 paths: spontaneous regression, stable existence, or malignant progression. Natural remission positively correlates with working outdoors due to decreased sun sensitivity, and has been observed in more than 50% of AKs. However, regressed lesions easily reappear over time [2].

The risk of malignant transformation of AK into an invasive SCC has been investigated in many studies. A 0.6% progression rate for a single AK was reported over 1 year, and 2.6% in 4 years [1]; in a 20-year period, this rate ranges from 0.025% to 20% [2]. The reason for such a wide difference is mainly the lack of a consensus definition of AK, with no risk stratification according to AK features. AK clinical presentation is highly polymorphic, with a variable combination of erythema, hyperkeratosis, and telangiectasia. In this scenario, AKs with rapid growth, bleeding, ulceration, induration and inflammation, and those >1 cm in size are at increased risk of progression to invasive SCC [3].

There is extensive evidence regarding AK risk factors. For instance, UV irradiation promotes carcinogenesis through the induction of p53 mutations, which elude cell-cycle checkpoints and promote the uncontrolled proliferation of dysplastic keratinocytes [2]. Recent advances confirm the influential role of UVB rays in the formation of thymidine dimers in the DNA and RNA of keratinocytes [2]. As a consequence, cumulative sun exposure is closely related to the onset of AK and SCC in the photo-exposed areas [4]. Both a history of sunburns, mainly those occurring in childhood [5], and chronic sun exposure (due to outdoor occupations or hobbies) increase the risk of developing AK, with an increasing trend towards older ages [4]. Moreover, the most susceptible subjects have fair skin phototypes [4] or are immunosuppressed (eg, transplant recipients and people with genetic disorders affecting DNA-repair mechanisms) [2]. Additional risk factors are male sex, a smoking habit, and the assumption of photosensitizing drugs [6,7]. The assumption of drugs that target the skin by any mechanism (eg, dermal deposit, skin thinning), such as oral retinoids, topical retinoids, tetracycline, macrolides, aminouquinolines, amidarone, and methoxypsoralen, make the skin more vulnerable to sun damage [7].

In 2018, the European Medicines Agency (EMA) released a warning concerning the risk of developing non-melanoma skin cancer (NMSC) from the use of thiazide diuretics [8]. The EMA Pharmacovigilance Risk Assessment Committee based this warning on the results of a Danish case-control study that found dose-response relationships between the long-term intake of hydrochlorothiazide and the risk of developing basal cell carcinoma and SCC [9]. Therefore, patients assuming hydrochlorothiazide alone or in combination with other diuretics, or nondiuretic antihypertensives, especially those with prior NMSC, are recommended to apply sunscreen daily and to attend regular dermatological check-ups. Prompted by this warning, we performed a prospective, single-center case-control study to evaluate a possible association between the use of photosensitizing drugs and the development of AK. A secondary aim of the study was to identify a possible association between any medication other than those primarily examined and AK.

Materials and Methods

Over a 6-month period, 90 AK cases were recruited consecutively from the dedicated NMSC Outpatient Service and 90 controls were recruited from several services of general dermatology at the Sant’Orsola-Malpighi Hospital. The study was approved by Central Emilia Wide Area Ethical Committee; it started on January 1, 2020, and ended on May 31, 2020.

A cut-off age higher than 60 years was set as an inclusion criterion for both groups. A medical history of AK or NMSC was an exclusion criterion for controls. All patients provided written informed consent for enrollment in the study.

To collect information on sociodemographic characteristics, skin phototype, cumulative sun exposure, and drug intake, patients were interviewed on a standardized questionnaire and then examined by an experienced dermatologist. Sun exposure was considered high in the case of more than a 5-year outdoor occupation or more than 10 years of outdoor recreational exposure. The survey also inquired about the long-term use of any class of medications, including drugs taken for at least 2 consecutive years and withdrawn within 3 months of the index date. Data recorded included the drug’s active ingredient, daily dosage, duration of therapy and, in case of dosage variation, the new dosage and year of variation. For each patient, cumulative exposure was calculated as the product of the duration of treatment multiplied by the daily dosage (dose unit-years).

Statistical Analysis

Continuous data were described by means and standard deviations (SD) or by median and interquartile ranges in case of a strongly asymmetric distribution (eg, exposure to drugs). For each categorical variable, we reported the absolute and relative frequencies expressed as percentages.

The comparison between cases and controls was performed using the t-test for continuous variables with a normal
distribution (eg, age) and the Mann-Whitney test for continuous variables with a skewed distribution (eg, drug exposure). Pearson’s chi-square test and Fisher’s exact test were used for comparisons of categorical variables. To assess an association between drug exposure and AK development, we used a multiple logistic regression model adjusted for the possible confounding effects of sociodemographic characteristics. The results of logistic regression were expressed as odds ratios (ORs) and confidence intervals (95% CI).

Statistical significance was set at P = .05. The analyses were conducted using the statistical software Stata version 15 (StataCorp, College Station, TX, USA).

Results

Overall, 180 patients were assessed, 90 cases and 90 controls (Table 1). The 2 groups differed significantly in age, sex, skin type, and recreational sun exposure (P < .001). Compared with controls, cases were older (mean, 79.4 vs. 73.3 years), more frequently male (73.3% vs. 38.9%), and more likely to have skin phototype I-II (52.2% vs. 14.4%). Combined sun exposure was lacking in 11.1% of cases and 46.6% of controls, mild-moderate in 4.4% and 18.9%, and high in 84.4% and 34.4%, respectively. No difference in terms of educational level was observed between the groups.

Drug exposure differed between groups for 2 classes of medications: angiotensin receptor blockers (ARBs) and anti-platelet drugs (Table 2). Similar proportions of patients took ARBs in the case and control groups (22.2% vs. 18.9%); however, the cumulative exposure was significantly higher in cases (P < .015). On the other hand, more than twice as many cases than controls took antiplatelet drugs (48.9% vs. 22.2%). No association was found between AK and other drugs, including thiazides and other diuretics, statins, β-blockers, calcium channel blockers, ACE inhibitors, anticoagulants (warfarin and novel oral anticoagulants) and the antiarrhythmic drug amiodarone (data not shown).

The exposure to ARBs and antiplatelet agents was categorized into 3 classes: high, low, and no exposure. Cut-off values of 750 and 1100 unit-years, respectively for ARBs and antiplatelet drugs, were used to distinguish high vs. low exposure. These new variables were included in a logistic regression model, adjusted for age, sex, skin type, and sun exposure (Table 3). Even after adjusting for sociodemographic features, the exposure to ARBs and antiplatelet agents was significantly associated with the presence of AK. An increase in the probability of AK was found only with high exposure to ARBs (OR = 13.6; 95% CI, 2.0–93.8). The low exposure to antiplatelet agents was not significant at the statistical analysis (OR = 3.31; 95% CI, 0.86–12.7), but the high exposure was significant (OR = 4.38; 95% CI, 1.16–16.60), showing a dose-dependent association.

### Table 1. Sociodemographic Features of Cases and Controls

| Factor                        | Cases (n = 90) | Controls (n = 90) | P    |
|-------------------------------|----------------|------------------|------|
| Age, mean ± SD                | 79.4 ± 7.2     | 73.3 ± 8.6       | <.001|
| Sex, No. (%)                  |                |                  |      |
| Male                          | 66 (73.3)      | 35 (38.9)        | <.001|
| Female                        | 24 (26.7)      | 55 (61.1)        |      |
| Education, No. (%)            |                |                  | 103  |
| Primary school                | 37 (41.1)      | 26 (28.9)        |      |
| Middle school                 | 19 (21.1)      | 18 (20.0)        |      |
| High school                   | 23 (25.6)      | 23 (25.6)        |      |
| University degree             | 11 (12.2)      | 23 (25.6)        |      |
| Skin phototype, No. (%)       |                |                  | <.001|
| I-II                          | 47 (52.2)      | 13 (14.4)        |      |
| III-IV                        | 43 (47.8)      | 77 (85.6)        |      |
| Sun exposure at work, No. (%) |                |                  | 0.7  |
| Absent                        | 12 (13.3)      | 5 (5.6)          |      |
| Recreational sun exposure, No. (%) |            |                  | <.001|
| Absent                        | 16 (17.8)      | 45 (50.0)        |      |
| Mild-moderate                 | 4 (4.4)        | 17 (18.9)        |      |
| High                          | 70 (77.8)      | 28 (31.1)        |      |
| Combined sun exposure, No. (%)|                |                  | <0.001|
| Absent                        | 10 (11.1)      | 42 (46.7)        |      |
| Mild-moderate                 | 4 (4.4)        | 17 (18.9)        |      |
| High                          | 76 (84.4)      | 31 (34.4)        |      |
### Table 2. Frequency and Duration of Exposure to the Examined Drugs

| Drug Class                  | Statistical Parameter | Cases (n = 90) | Controls (n = 90) | p   |
|-----------------------------|-----------------------|----------------|-------------------|-----|
| Angiotensin receptor blockers | n (%) 20 (22.2)       | 17 (18.9)      | .580              |
| Statistical Parameter       | Exposure 960 [469-2360] | 300 [90-750]  | .015              |
| Antiplatelet drugs          | n (%) 44 (48.9)       | 20 (22.2)      | <.001             |
| Statistical Parameter       | Exposure 1100 [750-1780] | 750 [300-1215] | .037              |
| Statins                     | n (%) 29 (32.2)       | 30 (33.3)      | .874              |
| Statistical Parameter       | Exposure 110 [80-180]  | 100 [60 – 190] | .382              |
| Calcium channel blockers    | n (%) 15 (16.7)       | 18 (20.0)      | .563              |
| Statistical Parameter       | Exposure 60 [35-100]   | 80 [40-240]    | .638              |
| Beta-blockers               | n (%) 29 (32.2)       | 24 (26.7)      | .414              |
| Statistical Parameter       | Exposure 400 [60-1100] | 97.5 [20-860]  | .133              |
| ACE inhibitors              | n (%) 29 (32.2)       | 29 (32.2)      | 1.0               |
| Statistical Parameter       | Exposure 52.5 [45-120] | 55 [27.5-180]  | .870              |
| Warfarin                    | n (%) 7 (7.8)         | 8 (8.9)        | .787              |
| Statistical Parameter       | Exposure 45 [20-115]   | 50 [22.5-97.5] | 1.0               |
| Novel oral anticoagulants   | n (%) 2 (2.2)         | 5 (5.6)        | .444              |
| Statistical Parameter       | Exposure 10 [5-15]     | 75 [40-110]    | .171              |
| Thiazides                   | n (%) 20 (22.2)       | 12 (13.3)      | .119              |
| Statistical Parameter       | Exposure 225 [87.5-412.5] | 137.5 [56.25-387.5] | .402   |
| Loop diuretics              | n (%) 17 (18.9)       | 15 (16.7)      | .697              |
| Statistical Parameter       | Exposure 165 [50-250]  | 150 [50-400]   | .406              |

Drug exposure was calculated as the daily dose multiplied by the years of therapy (dosage unit-years) and is reported as the median (interquartile range). ACE = angiotensin-converting enzyme.

### Table 3. Multiple Logistic Regression Model Predicting Actinic Keratosis

| Variables                        | No. | OR (95% CI) | p   |
|----------------------------------|-----|-------------|-----|
| ARBs                             |     |             |     |
| • No exposure                    | 143 | 1.00        |     |
| • Low exposure                   | 18  | 0.25 (0.05 - 1.32) | .05 |
| • High exposure (>750 dose unit-years) | 19  | 13.6 (2.0 – 93.8) | .001|
| Antiplatelet agents              |     |             |     |
| • No exposure                    | 116 | 1.00        |     |
| • Low exposure                   | 31  | 3.31 (0.86 – 12.69) | .10 |
| • High exposure (>1100 dose unit-years) | 33  | 4.38 (1.16 – 16.60) | .04 |

Note: the model is adjusted for age, sex, skin type, and sun exposure.

ARBs = angiotensin receptor blockers; CI = confidence interval; OR = odds ratio.

### Table 4. Concomitant Exposure to ARBs and Antiplatelet Drugs

| Cases | Controls |
|-------|----------|
|       | Exposure to Antiplatelet Drugs, n (%) | Exposure to Antiplatelet Drugs, n (%) |
|       | Low | Moderate | High | Absent | Low | High |
| Exposure to ARBs | Low | 38 (42.2) | 16 (17.8) | 16 (17.8) | 58 (64.4) | 8 (8.9) | 7 (7.8) |
|       | Moderate | 3 (3.3) | 1 (1.1) | 2 (2.2) | 8 (8.9) | 4 (4.4) | 0 (0) |
|       | High | 5 (5.6) | 1 (1.1) | 8 (8.9) | 4 (4.4) | 1 (1.1) | 0 (0) |

ARBs = angiotensin receptor blockers.
Eight cases were concomitantly exposed to ARBs and antiplatelet drugs, whereas no double exposure was found in controls (Table 4).

**Discussion**

Two studies based on Danish national data showed a dose-dependent, cumulative association between the photosensitizing activity of hydrochlorothiazide and NMSC, including basal cell carcinoma and SCC [9,10]. One of these studies highlighted a 7-fold increased risk of SCC lip cancer in exposed subjects [10]. The other study found the strongest associations with: a cumulative hydrochlorothiazide dose >200 mg, female sex, upper or lower limbs, and age ≤50 years [9]. The postulated pathogenetic mechanism is photosensitivity due to hydrochlorothiazide, which is well documented and could enhance photocarcinogenesis [1-14].

Subsequently, further papers on the association between photosensitizing agents and NMSC were published and yielded conflicting results. Indeed, some studies showed no association between hydrochlorothiazide and NMSC, and some authors raised concerns about the methodological limitations of the 2 Danish studies [15-24].

In contrast to the Danish studies, our study did not find any evidence of an association between thiazide diuretics and actinic keratosis, probably due to the limited use of thiazides in our sample. Instead, our study showed that high exposure to ARBs and even low exposure to antiplatelet drugs, in a dose-dependent pattern, represent significant risk factors for the development of AK.

In the literature, a similar study conducted in 1999 assessed the impact of photosensitizing drugs on the development of AK. However, the number of patients was small (34 cases and 34 controls), and the use of cardiovascular drugs was also considerably low [7].

Other recent studies demonstrated the induction of photosensitivity in patients taking ARBs, and hypothesized drug-driven carcinogenesis favored by sun exposure [25-29]. However, as for hydrochlorothiazide, the results of different studies are contradictory. Conflicting evidence regarding the use of antiplatelet agents comes from a Brazilian case-control study, which demonstrated a protective effect of acetysalicylic acid on the development of AK [30]. This study enrolled 74 cases and 216 controls, and the median duration of therapy was 36 months. The use of acetysalicylic acid was an independent protective factor for AK onset since it was associated with a lower AK count on the face and upper extremities, regardless of concomitant risk factors. In our study, ticlopidine and clopidogrel were used by only 3 cases and 1 control: for this reason, we included all antiplatelet agents within a single group.

The main limitation of our study is that it is inadequately powered to detected mild differences in drug exposures between cases and controls. For instance, the differential percentage in the use of oral diuretic thiazides (22.2% vs. 13.3%) would require a sample size of 288 cases and 288 controls to be significant at $P < .05$, with 80% power.

Furthermore, cases were not closely matched to controls in terms of age, sex, or skin phototype. Consecutive recruitment of patients was pursued to avoid selection bias but implied a significant inhomogeneity in the 2 groups. The study design foresaw these results, and aimed to adjust all possible confounding factors by multivariate analysis.

In southern Europe, the high prevalence of AK made the recruitment of controls extremely difficult in older age groups. Besides, the case group had significantly more men and fair-skinned individuals. The sex difference between the groups may have affected their use of sun-protective measures, as women are more inclined to apply sunscreen. However, sun-protective behaviors were not recorded in our survey. They could have affected the quality of our data due to the dose-dependent ability of sun-blockers to increase the AK remission rate and prevent the development of new lesions [2].

Another limitation of our study is the inclusion of patients using multidrug therapies, which, however, reflects real practices and the disease burden of elderly patients. The current study was underpowered to identify potential synergic or antagonistic effects of the simultaneous use of multiple drugs. Supplementary analyses adjusted for the concomitant use of antihypertensive/diuretic drugs should be performed in a larger series. A possible synergistic effect of taking two photosensitizing drugs favoring AK genesis could not be excluded. In our study, the number of patients on both antiplatelet and ARB therapy was very low. Table 4 shows that none of the controls with high exposure to antiplatelet agents was exposed to ARBs at the same time. In contrast, the 8 patients on dual therapy with high exposure to antiplatelet drugs and ARBs were in the case group. Therefore, a more extensive study with a larger population size is warranted to characterize patients taking both drugs, and to define the attributable risk of developing AK for each medication.

**Conclusions**

Our study was designed to investigate a possible association of photosensitizing drugs and AK. Our results suggest a correlation between the use of ARBs or antiplatelet agents and the onset of AK. ARBs possess a known photosensitizing effect, which could be the missing link between their use and the development of AK. Antiplatelet agents do not induce photosensitivity, and their association with AK remains unknown. Further studies are needed to assess the pro-car-
cinogenic potentials of these 2 classes of drugs, in order to prompt adequate dermatological screening and sun protection, mainly in patients with a medical history of NMSC.

References

1. Criscione VD, Weinstock MA, Naylor MF, et al; Department of Veteran Affairs Topical Tretinoin Chemoprevention Trial Group. Actinic keratoses: Natural history and risk of malignant transformation in the Veterans Affairs Topical Tretinoin Chemoprevention Trial. *Cancer*. 2009;115(11):2523. DOI: 10.1002/cncr.24284. PMID: 19382202.
2. Siegel JA, Korgavkar K, Weinstock MA. Current perspective on actinic keratosis: a review. *Br J Dermatol*. 2017;177(2):350-358. DOI: 10.1111/bjd.14852. PMID: 27500794.
3. Quaedvlieg PJ, Tirsi E, Thissen MR, et al. Actinic keratosis: how to differentiate the good from the bad ones? *Eur J Dermatol*. 2006;16(4):335-339. PMID: 16935787.
4. Frost CA, Green AC, Williams GM. The prevalence and determinants of solar keratoses at a subtropical latitude (Queensland, Australia). *Br J Dermatol*. 1999;139(6):1033-1039. DOI: 10.1046/j.1365-2133.1998.00260.x. PMID: 9990367.
5. Placzek M, Eberlein-König B, Przybilla B. Association between actinic keratoses and potentially photosensitizing drugs. *N Engl J Med*. 1999;341(19):1474-1475. DOI: 10.1056/NEJM199910143411915. PMID: 10577103.
6. de Berker D, McGregor JM, Mohd Mustapa MF, Exton LS, Hughes BR. British Association of Dermatologists’ guidelines for the care of patients with actinic keratosis 2017. *Br J Dermatol*. 2017;176(1):20-43. DOI: 10.1111/bjd.15107. PMID: 28098380.
7. Placek Z, Eberlein-König B, Przybilla B. Association between actinic keratoses and potentially photosensitizing drugs. *N Engl J Med*. 1999;341(19):1474-1475. DOI: 10.1056/NEJM199910143411915. PMID: 10577103.
8. European Medicines Agency—Pharmacovigilance Risk Assessment Committee (PRAC). PRAC recommendations on signals. 1 October 2018. Accessed: February 14, 2021. Available at: https://www.emea.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-3-6-september-2018-prac-meeting_en-0.pdf.
9. Pedersen SA, Gaist D, Schmidt SAJ, Holmich LR, Fris S, Pottegård A. Hydrochlorothiazide use and risk of nonmelanoma skin cancer: A nationwide case-control study from Denmark. *J Am Acad Dermatol* 2018;78(4):673-681.e9. DOI: 10.1016/j.jaad.2017.11.042. PMID: 29217346.
10. Pottegård A, Hallas J, Olesen M, et al. Hydrochlorothiazide use is strongly associated with risk of lip cancer. *J Intern Med*. 2017;282(4):322–331. DOI: 10.1111/joim.12629. PMID: 28480532.
11. Friedman GD, Asgari MM, Warton EM, Chan J, Habel LA. Antihypertensive drugs and lip cancer in non-Hispanic whites. Arch Intern Med. 2012;172(16):1246-1251. DOI: 10.1001/archinternmed.2012.2754. PMID: 22869299.
12. O’Gorman SM, Murphy GM. Photosensitizing medications and photocarcinogenesis. *Photodermatol Photomed Photod动态*. 2014;30(1):8-14. DOI: 10.1111/jphp.12085. PMID: 24393207.
13. Jensen AO, Thomsen HF, Engebret MC, Olesen AB, Sørensen HT, Karagas MR. Use of photosensitising diuretics and risk of skin cancer: a population-based case-control study. *Br J Cancer*. 2008;99(9):1522-1528. DOI: 10.1038/sj.bjc.6604686. PMID: 18813314.
14. Schmidt SAJ, Schmidt M, Mehnert F, et al. Use of antihypertensive drugs and risk of skin cancer. *J Eur Acad Dermatol Venereol*. 2015;29(8):1545-1554. DOI: 10.1111/jd.12921. PMID: 25640031.
15. Pottegård A, Pedersen SA, Schmidt SAJ, et al. Use of hydrochlorothiazide and risk of skin cancer: a nationwide Taiwanese case-control study. *Br J Cancer*. 2019;121(11):973-978. DOI: 10.1038/s41416-019-0613-4. PMID: 31673105.
16. Han S, Wolfe CM, Angnardo L, et al. Hydrochlorothiazide use and increased squamous cell carcinoma burden in a high-risk Mohs population: a cross-sectional study. *Dermatol Surg*. 2020;46(5):704-708. DOI: 10.1097/DS.0000000000001875.
17. Park E, Lee Y, Jue MS. Hydrochlorothiazide use and the risk of skin cancer in patients with hypertensive disorder: a nationwide retrospective cohort study from Korea. *Korean J Intern Med*. 2019;35(4):917-928. DOI: 10.3904/kjim.2019.218.
18. Olde Engberink RHG, van der Hoeven NV, Zwinderman AH, van den Born BH. Hydrochlorothiazide en huidkanker [Hydrochlorothiazide and skin cancer]. *Ned Tijdsschr Geneeskd*. 2019;163:D3755.
19. MHRA drug safety update: hydrochlorothiazide and non-melanoma skin cancer. *Drug Ther Bull*. 2019;57(5):70. DOI: 10.1136/dtb.2019.00023. PMID: 31018928.
20. Morales DR, Pucarariu A, Slattery J, Kurz X. Association between hydrochlorothiazide exposure and different incident skin, lip and oral cavity cancers: A series of population-based nested case-control studies. *Br J Clin Pharmacol*. 2020;86(7):1336-1345. DOI: 10.1111/bcp.14245. PMID: 32068906.
21. Kreutz R, Algharably EAH, Douros A. Reviewing the effects of thiazide and thiazide-like diuretics as photosensitizing drugs on the risk of skin cancer. *J Hypertens*. 2019;37(10):1950-1958. DOI: 10.1097/HJH.0000000000002136. PMID: 31145177.
22. Becquart O, Guilott B, Bourrain J-L, Duflos C, Du-Thanh A. Risque de cancers cutanés sous hydrochlorothiazide: revue systématique [Hydrochlorothiazide use and risk of skin cancers: A systematic review]. *Rev Med Interne*. 2019;40(9):617-622. DOI: 10.1016/j.remin.2019.04.008. PMID: 31103131.
23. Shin D, Lee ES, Kim J, Guerra L, Naik D, Prida X. Association between the use of thiazide diuretics and the risk of skin cancers: a meta-analysis of observational studies. *J Clin Med Res*. 2019;11(4):247-255. DOI: 10.14740/jocmr3744. PMID: 30937114.
24. Facconti L, Ferro A, Webb AJ, Cruickshank JK, Chowienczyk PJ; British and Irish Hypertension Society. Hydrochlorothiazide and the risk of skin cancer. A scientific statement of the British and Irish Hypertension Society. *J Hum Hypertens*. 2019;33(4):257-258. DOI: 10.1038/s41371-019-0190-2. PMID: 3082544.
25. Viola E, Coggiola Pittoni A, Drahos A, Moretti U, Conforti A. Photosensitivity with angiotensin II receptor blockers: a retrospective study using data from VigiBase®. *Drug Saf*. 2019;42(10):889-894. DOI: 10.1007/s40264-019-00323-7. PMID: 25681768.
26. Nardone B, Orrall KA, Vakharia PC, West DP. Skin cancer associated with commercially prescribed drugs: tumor necrosis factor alpha inhibitors (TNF-αIs), angiotensin-receptor blockers (ARBs), phosphodiesterase type 5 inhibitors (PDE5Is) and statins—weighing the evidence. *Expert Opin Drug Saf*. 2018;17(2):139-147. DOI: 10.1080/14740338.2018.1400530. PMID: 29103328.
27. Nardone B, Majewski S, Kim AS, et al. Melanoma and non-melanoma skin cancer associated with angiotensin-converting-enzyme inhibitors, angiotensin-receptor blockers and thiazides: a matched cohort study. *Drug Saf.* 2017;40(3):249–255. DOI: 10.1007/s40264-016-0487-9. PMID: 27943160.

28. Moscarelli L, Zanazzi M, Mancini G, et al. Keratinocyte cancer prevention with ACE inhibitors, angiotensin receptor blockers or their combination in renal transplant recipients. *Clin Nephrol.* 2010;73:439-445. DOI: 10.5414/CNP73439. PMID: 20497756

29. Christian JB, Lapane KL, Hume AL, Eaton CB, Weinstock MA; VATTC Trial. Association of ACE inhibitors and angiotensin receptor blockers with keratinocyte cancer prevention in the randomized VATTC trial. *J Natl Cancer Inst.* 2008;100:1223-1232. DOI: 10.1093/jnci/djn262. PMID: 18728281

30. Schmitt J, Miot H. Oral acetylsalicylic acid and prevalence of actinic keratosis. *Rev Assoc Médica Bras.* 2014;60(2):131-138. DOI: 10.1590/1806-9282.60.02.010. PMID: 24919000.